Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?

被引：1
|
作者：
Ernest-Suarez, Kenneth [1 ]
Lu, Cathy [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 57卷 / 06期
关键词：
D O I：
10.1111/apt.17351
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：733 / 734
页数：2
相关论文
共 48 条
  • [21] RATES OF DISEASE- RELATED HOSPITALIZATION AND COLECTOMY IN REAL-WORLD PATIENTS WITH ULCERATIVE COLITIS ON ANTI-TNF AGENTS: EVIDENCE FROM A SYSTEMATIC REVIEW
    Gautam, R.
    Gutta, D.
    Prasanna, R.
    Rai, M. K.
    VALUE IN HEALTH, 2022, 25 (12) : S36 - S36
  • [22] Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 1-year maintenance therapy results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1470 - I1471
  • [23] Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study
    Hupe, Marianne
    Riviere, Pauline
    Nancey, Stephane
    Roblin, Xavier
    Altwegg, Romain
    Filippi, Jerome
    Fumery, Mathurin
    Bouguen, Guillaume
    Peyrin-Biroulet, Laurent
    Bourreille, Arnaud
    Caillo, Ludovic
    Simon, Mireille
    Goutorbe, Felix
    Laharie, David
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) : 852 - 860
  • [24] Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 2-year maintenance therapy results from the prospective, observational RUN-UC study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Howaldt, S.
    Mohl, W.
    Efken, P.
    Ehehalt, R.
    Kahl, M.
    Krause, T.
    Trentmann, L.
    Luegering, A.
    Schnoy, E.
    Jochum, C.
    Salmon, S. Fajardo
    Hartmann, P.
    Gilman, E.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2131 - i2132
  • [25] 1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
    Dalal, Rahul S.
    Sharma, Puza P.
    Bains, Kanwal
    Pruce, Jordan C.
    Allegretti, Jessica R.
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (08) : 1419 - 1422
  • [26] Comparison of the efficacy of a second intravenous or subcutaneous anti-TNF in the treatment of ulcerative colitis: Real-world data from the ENEIDA registry
    Torres-Rodriguez, P.
    Canete, F.
    Calafat, M.
    Sanchez-Aldehuelo, R.
    Rivero, M.
    Iborra, M.
    Gonzalez-Vivo, M.
    Vera, I.
    de Castro, L.
    Bujanda, L.
    Barreiro-de Acosta, M.
    Calvet, X.
    Benitez, J. M.
    Llorente, M.
    Suris, G.
    Arias-Garcia, L.
    David, M.
    Castano-Garcia, A.
    Garcia-Alonso, F. J.
    Rufo, L.
    Ferrer, J. A.
    Camo, P.
    Gisbert, J. P.
    Huguet, J. M.
    Pajares, R.
    Morales, V.
    Llao, J.
    Rodriguez, A.
    Rodriguez, C.
    Navarro, M.
    Gomollon, F.
    Carrillo-Palau, M.
    Sese, E.
    Almela, P.
    Ramirez de la Piscina, P.
    Rodriguez-Lago, I.
    Papo, M.
    Vela, M.
    Manosa, M.
    Domenech, E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S463 - S464
  • [27] A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
    Hoque, S.
    Boccaletti, S.
    Puenpatom, A.
    Brown, C.
    Black, C.
    Roberts, J.
    Rajkovic, I.
    Milligan, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S394 - S394
  • [28] EFFICACY AND SAFETY OF TOFACITINIB AFTER FAILURE OF ANTI-TNF AGENT IN PATIENTS WITH ULCERATIVE COLITIS: A US-BASED PROPENSITY MATCHED COHORT STUDY
    Kochhar, Gursimran S.
    Desai, Aakash
    Dulai, Parambir S.
    Cross, Raymond K.
    Farraye, Francis A.
    Regueiro, Miguel D.
    El-Hachem, Sandra
    GASTROENTEROLOGY, 2023, 164 (06) : S646 - S647
  • [29] Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)
    Bouguen, G.
    Nachury, M.
    Nancey, S.
    Bouhnik, Y.
    Bourreille, A.
    Altwegg, R.
    Vuitton, L.
    Buisson, A.
    Viennot, S.
    Laharie, D.
    Fumery, M.
    Gillettta, C.
    Uzzan, M.
    Delobel, J. B.
    Amiot, A.
    Peyrin-Biroulet, L.
    Gornet, J. M.
    Caillo, L.
    Roblin, X.
    Laviolle, B.
    Ahmim, M.
    Tron, C.
    Bendavid, C.
    Le Pabic, E.
    Landemaine, A.
    Hebuterne, X.
    GETAID
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i74 - i74
  • [30] Real-world drug treatment costs for ulcerative colitis and Crohn's disease patients treated with vedolizumab vs. anti-TNFα: Results from a German retrospective chart review study
    Campbell-Hill, S.
    Stein, D.
    Soni, M.
    Coombs, C.
    Ratsch, B.
    Khalid, J. M.
    Minda, K.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S504 - S504
12345